Moderna, Inc. (NASDAQ:MRNA) Receives $97.18 Consensus PT from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given an average recommendation of “Hold” by the twenty ratings firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $94.65.

Several research analysts recently commented on the stock. UBS Group reduced their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, September 13th. Barclays reduced their price objective on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a research note on Monday, September 16th. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Finally, Bank of America reduced their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th.

Moderna Price Performance

Shares of MRNA opened at $54.80 on Thursday. The company has a 50 day moving average price of $67.68 and a 200-day moving average price of $102.74. Moderna has a fifty-two week low of $52.26 and a fifty-two week high of $170.47. The stock has a market capitalization of $21.00 billion, a PE ratio of -3.50 and a beta of 1.66. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the company earned ($3.62) EPS. The company’s revenue was down 29.9% compared to the same quarter last year. Equities analysts predict that Moderna will post -9.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,184 shares of company stock valued at $2,037,931. Corporate insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stephens Inc. AR lifted its holdings in Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after purchasing an additional 245 shares in the last quarter. AustralianSuper Pty Ltd lifted its holdings in Moderna by 27.0% during the third quarter. AustralianSuper Pty Ltd now owns 14,507 shares of the company’s stock valued at $970,000 after purchasing an additional 3,084 shares in the last quarter. Meitav Investment House Ltd. lifted its holdings in Moderna by 96.6% during the third quarter. Meitav Investment House Ltd. now owns 226,903 shares of the company’s stock valued at $15,164,000 after purchasing an additional 111,475 shares in the last quarter. GSB Wealth Management LLC lifted its holdings in Moderna by 60.8% during the third quarter. GSB Wealth Management LLC now owns 5,292 shares of the company’s stock valued at $354,000 after purchasing an additional 2,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Moderna by 67.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 79,611 shares of the company’s stock valued at $5,320,000 after purchasing an additional 32,118 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.